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health care costs among type 2 diabetes patients. METHODS:
A pre-post conversion approach was adopted using an integrated
medical and pharmacy claims database from >50 managed care
health plans in the United States. Adults diagnosed with type 2
diabetes who converted to insulin pen therapy (FlexPenTM) from
either human or analog insulin vials between July 2001 and
December 2002 with no prior use of FlexPenTM for six months
were identiﬁed and retrospectively analyzed. Endpoints included
adherence (medication possession ratio (MPR)), follow-up time
adjusted odds ratio of hypoglycemic events, association between
adherence and hypoglycemic events in a Poisson multivariate
context, and diabetes-attributable (DA) and hypoglycemia-
attributable (HA) costs. RESULTS: A total of 1156 subjects were
identiﬁed and included (mean age 45.4 + 13.7; 51.5% previously
on human insulin vials). Post-conversion, adherence improved
signiﬁcantly (MPR: 69% vs. 62%; p < 0.01). Additionally, fewer
hypoglycemic events were observed [OR: 0.50 (CI: 0.37–0.68);
p < 0.05] and such events requiring either emergency department
visits and physician visits decreased by 56% [OR: 0.44 (CI:
0.21–0.92)] and 61% [0.39 (CI: 0.24–0.64)], respectively (p <
0.05). Incidence of hypoglycemic events in subjects with MPR >
70% as conﬁrmed by a Poisson multivariate analysis, dropped
by nearly two-thirds [0.35 (0.11–0.81); p < 0.05]. Total annual
HA costs fell 56% ($1415 vs. $627; p < 0.01), and total DA
costs fell 7% ($8827 vs. $8227; p < 0.01). CONCLUSIONS:
Converting to insulin pen therapy from administration with
vial/syringe was associated with improved adherence, which in
turn was correlated with fewer hypoglycemic events and lower
treatment costs among type 2 diabetes patients. Future studies
should examine the impact of earlier use of insulin pen therapy
on patient adherence as well as clinical and economic outcomes.
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OBJECTIVES: Comparisons of “real world” effectiveness of dia-
betes treatments within a single population are rare. We com-
pared glycemic response after the addition of any of the four
most commonly used therapeutic classes (metformin, sul-
fonylureas, insulin, thiazolidinediones) for type 2 diabetes.
METHODS: We studied 15,126 type 2 diabetes patients initiat-
ing a single new ntihyperglycemic therapeutic class (new user
design) in 1999–2000 in Kaiser (health plan in USA). In
ANCOVA models, we assessed pre-post (3–12 months after ini-
tiation) change in glycosylated hemoglobin (A1C), adjusted for
baseline A1C, other antihyperglycemic therapy, demographics,
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MELLITUS TYPE-2 PATIENTS
Sturkenboom MC1, Dieleman JP2,Van der Lei J2
1Erasmus University Medical Center, Soest,The Netherlands, 2Erasmus
University Medical Center, Rotterdam,The Netherlands
Switching from oral antidiabetics to insulin injection is perceived
as a major barrier by diabetes mellitus type-2 patients with fear
for injection of insulin, but little is known about the extent.
OBJECTIVE: To estimate the rate of starting insulin in newly
identiﬁed diabetes mellitus patients, in patients starting with a
combination of two oral antidiabetics and in patients with
uncontrolled HBA1c levels while taking two oral antidiabetic
agents. METHODS: A retrospective cohort study was conducted
in the IPCI general practice database during the period
1996–2004. Patients with diabetes mellitus type II (DM-2) were
classiﬁed as prevalent if DM-2 was diagnosed prior to entry in
follow-up and as incident if diagnosed during follow-up. Three
cohorts were identiﬁed to assess the rate and risk of starting
insulin. Cohort A: all incident DM-2 patients, cohort B: all
patients newly starting with a multiple pill oral combination
therapy. Cohort C was a subset of B and comprised all patients
on oral combination therapy who had uncontrolled HBA1c
levels after at least 3 months of treatment. RESULTS: The source
population comprised 5693 incident and 7456 prevalent DM-2
patients. In incident DM-2 patients 80% was treated pharma-
cologically within one year, 3% received an insulin based
regimen as initial treatment, 76% started on a single oral antidi-
abetic. The rate of starting insulin was 0.6/100 PY in patients of
cohort A, who started on oral treatment. The rate of starting
insulin was 6.6/100 PY for patients in cohort B (n = 1858). The
one-year risk of starting insulin in cohort C (n = 1167) was 3.8%
(2.1–5.5%) for patients with HBA1c between 7–8% and 14.3%
for patients with HBA1c above 8% at cohort entry. CONCLU-
SION: The rates and one-year risks of starting insulin are low
even in DM-2 patients who remain uncontrolled after at least
three months of oral combination therapy.
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OBJECTIVE: This study sought to evaluate the impact of con-
verting to insulin administration with an analog insulin pen
device from vial/syringe on adherence, hypoglycemic events, and
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behaviors, medication adherence, clinical factors, and quality of
care. Cross-product terms were speciﬁed to evaluate differential
effectiveness for subjects with differing clinical conditions includ-
ing renal insufﬁciency based on GFR, obesity, longer duration of
diabetes, and older age. RESULTS: A1C was lowered by 1.14
points (95%CI: 1.11–1.17) within one year after initiating new
therapy, but only 30.2% (95%CI: 29.2–31.1%) achieved target
(A1C < 7%). Mean A1C was 9.01 (8.98–9.04) prior to initia-
tion and 7.87 (7.85–7.90) at 3–12 months after baseline. While
baseline disease severity differed across initiators of each thera-
peutic class, there were no statistically signiﬁcant differences in
glycemic lowering across classes, or across clinical conditions.
CONCLUSIONS: Therapy initiation resulted in an impressive
population-level beneﬁt, similar in magnitude to that reported in
randomized trials. Nonetheless, most patients failed to achieve
glycemic targets after initiation possibly because providers had
delayed intensiﬁcation or patients failed to ﬁll earlier prescrip-
tions until they had advanced to very poor control. While no
population-level differences in response by therapy were
detected, in any one patient, differential response by class can
not be excluded. The substantial glycemic response following ini-
tiation suggests that providers are probably choosing therapies
for intensiﬁcation wisely, but that earlier addition of a new agent
may be beneﬁcial.
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OBJECTIVES: Previous studies have shown that for patients
with type 2 diabetes, self monitoring of blood glucose (SMBG)
can improve glycemic control (with HbA1c improvements of
0.3–0.6%, depending on treatment received). This in turn, can
reduce risks of disease complications. Because monitoring sup-
plies can have high acquisition costs, country-speciﬁc evaluations
of SMBG cost-effectiveness are needed. The aim of this analysis
was to estimate, within a US setting, the cost-effectiveness of
using SMBG. METHODS: A validated, published model for type
2 diabetes (The CORE Diabetes Model) was used to project
improvements in quality-adjusted life expectancy (QALE), long-
term costs and cost-effectiveness of SMBG. A series of Markov
models simulated the progression of diabetes-related complica-
tions (cardiovascular, neuropathy, renal and eye disease). Tran-
sition probabilities and HbA1c-dependent adjustments came
from major epidemiological studies. Costs of complications were
derived from published sources. From a US third party payer per-
spective, direct costs of diabetes complications and of SMBG
were projected over patient lifetimes. Outcomes were discounted
at 3% annually. RESULTS: Depending on type of treatment
(diet/exercise, oral medications, or insulin), greater glycemic
control with SMBG improved (discounted) QALE by 0.13 to
0.32 QALYs and increased total costs by $2089 to $4661 per
patient. The resulting incremental cost-effectiveness ratios
ranged from $13,848 to $35,880 per QALY gained, and were
well within current willingness-to-pay limits. SMBG was most
cost-effective in patients being treated with oral antidiabetic
medication, and those being treated with insulin therapy. CON-
CLUSIONS: Within the three treatment regimens examined, the
addition of SMBG was associated with increased glycemic
control and with improved clinical and economic long-term out-
comes. The incremental cost-effectiveness ratios were of magni-
tudes typically considered to indicate good value for money.
Additional comparative studies are needed to further assess Util-
ities and other standard outcomes associated with SMBG in
patients with type 2 diabetes.
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OBJECTIVES: Technological innovations may be cost-
increasing and quality-improving (CIQI), cost-saving and
quality-improving (dominant), cost-increasing and quality-
decreasing (dominated), or cost-saving and quality-decreasing
(CSQD). We endeavored to determine how cost-utility analyses
of new medical technologies are distributed across these cate-
gories. METHODS: We systematically searched computerized
databases including MEDLINE, HealthSTAR, CancerLit,
Current Contents and EconLit to identify cost-utility analyses
published in 2002 to 2003. Trained auditors summarized each
study using standardized forms. All costs were converted to 2002
US dollars. RESULTS: We identiﬁed 640 separate published cost
utility analyses. These papers compared 657 interventions
against a standard. Of analyzed interventions, 79.0% (519) were
CIQI, 13.5% (89) were dominant, 6.7% (44) were dominated,
but only 0.8% (5) were CSQD. Among CIQI interventions,
64.6% (335) had a cost-effectiveness ratio (CER) below $50,000
per QALY and 79.0% (410) had a CER below $100,000 per
QALY. Among CSQD interventions, 60% (3) had a CER below
$50,000 per QALY and 2 had a CER above $100,000 per QALY.
CONCLUSIONS: Most published cost-utility analyses are per-
formed on CIQI technologies, and most of these have a CER
below conventionally accepted thresholds. Cost-utility analyses
of CSQD technologies are extremely rare.
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OBJECTIVE: Solid organ transplants are among the most
resource intensive of treatments. There exists only limited knowl-
edge of the current costs of solid organ transplants in Canada
because existing studies were derived from single centres,
included different resource categories, covered different time
periods, and used different cost methodologies. The purpose
study was to derive population-based estimates of the direct
medical costs of kidney, liver, lung and heart transplans in British
Columbia (BC), Canada, from 1995 to 2003. METHODS:
Province wide resource utilization data were extracted from the
BC Transplant Society. This population-based registry includes
records of all persons undergoing solid organ transplantation in
BC. Unit cost data were obtained from publicly available
sources. Health resources categories included inpatient hospital
stays, outpatient visits, physician fees, laboratory and diagnostic
tests and immunosuppressant medications. Mean (standard devi-
ation (SD)) costs were derived separately for the transplant pro-
